A previous study in an experimental epilepsy model revealed the antiepileptic effects of low-dose bumetanide, whose concentration in the brain was incompatible with NKCC1 inhibition51, suggesting that target(s) other than NKCC1 may contribute to the antiepileptic effect of bumetanide. The gene discussed is SLC12A2; the disease is epilepsy.